Average Vol (30d)
0.0046 - 0.0052
0.0010 - 0.1840
Net Dividend Yield
MYDX Latest Activity
- More Posts about MYDX Here
Latest News for: MyDx, Inc.
Published: Tuesday July 18, 2017
SAN DIEGO, July 18, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer initially designed for cannabis professionals and retail consumers to measure the chemicals in cannabis and track their feedback on how each sample is impacting their physiology, today announced that all previously reported variable toxic debts have been satisfied through the unauthorized conversion of the Crown Bridge note and has also filed a lawsuit against its former COO and other defendants who have attempted to create a competitive advantage with its anticipated product launch of its air quality sensor: AeroDx®. On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against a series of Defendants who have allegedly engaged in unfair business practices, made false statements about the Company, its products, and Mr. Yazbeck at investor events and on online investor platforms. There can be no assurance about the results or on the outcome of the lawsuit, however, the company took aggressive steps it felt were necessary to protect its business and its shareholders.
Published: Thursday June 29, 2017
Company Receives Initial Product Sales from its Canadian Campaign as it Ramps Up Over the Coming Month SAN DIEGO , June 29, 2017 /PRNewswire/ -- MyDx, Inc. (OTCQB:MYDX), a science and technology company ...
Published: Monday June 19, 2017
SAN DIEGO, June 19, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments they report it alleviates, today announced a definitive agreement with BlackSwan, a developer and retailer of custom vaporizers, to provide a community engagement software platform to support its new product development initiatives under the terms of MyDx360. As part of the MyDx360 agreement, BlackSwan chose from one of MyDx's base chemical formulations that best alleviated pain and inflammation according to the MyDx community. From there, MyDx software enabled BlackSwan to "boost" that formula by changing various cannabinoid and terpene parameters as well as other natural organic terpenes to come to a final formula uniquely formulated by BlackSwan.
MYDX ChatOnly logged in users are allowed to enter the chat
Join Chat by Logging in -or- Becoming a Registered Member